New shot tested to tame stubborn high blood pressure

NCT ID NCT05562934

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a new injectable drug called XXB750 for people with resistant high blood pressure, meaning their blood pressure stays high despite taking three or more standard pills. Over 20 weeks, researchers compared different doses of XXB750 to a placebo (a dummy injection) to see which worked best and was safest. All participants continued taking their regular blood pressure medications during the study.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alliance for Multispecialty Resrch

Wichita, Kansas, 67207, United States
American Clinical Trials

Acworth, Georgia, 30101, United States
Anderson Medical Research

Ft. Washington, Maryland, 20744, United States
Canvas Clinical Research

Lake Worth, Florida, 33467, United States
Capitol Cardiology Associates

Lanham, Maryland, 20706, United States
Cardiology Partners Clinical Research Institute

Wellington, Florida, 33449, United States
Clinical Trials Research Sacramento

Sacramento, California, 95821-2134, United States
Dominion Medical Associates

Richmond, Virginia, 23219, United States
Inpatient Research Clinical LLC

Miami Lakes, Florida, 33014, United States
Jacksonville Center for Clinical Research

Jacksonville, Florida, 32216, United States
MD Medical Research

Oxon Hill, Maryland, 20745, United States
Manassas Clinical Research Center

Manassas, Virginia, 20110, United States
NexGen Research

Lima, Ohio, 45801, United States
Novartis Investigative Site

Adelaide, South Australia, 5000, Australia
Novartis Investigative Site

Perth, Western Australia, 6000, Australia
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Vienna, 1190, Austria
Novartis Investigative Site

Pleven, 5800, Bulgaria
Novartis Investigative Site

Sofia, 1202, Bulgaria
Novartis Investigative Site

Sofia, 1233, Bulgaria
Novartis Investigative Site

Sofia, 1709, Bulgaria
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014010, China
Novartis Investigative Site

Beijing, 101200, China
Novartis Investigative Site

Qingdao, 266000, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Brandýs nad Labem, Czech Republic, 250 01, Czechia
Novartis Investigative Site

Prague, 128 08, Czechia
Novartis Investigative Site

Bobigny, 93009, France
Novartis Investigative Site

Lille, 59000, France
Novartis Investigative Site

Paris, 75015, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Elsterwerda, Brandenburg, 04910, Germany
Novartis Investigative Site

Frankfurt am Main, Hesse, 60594, Germany
Novartis Investigative Site

Berlin, 10787, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Ulm, 89077, Germany
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Milan, MI, 20122, Italy
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Pisa, PI, 56124, Italy
Novartis Investigative Site

Chikushino-shi, Fukuka, 818-8516, Japan
Novartis Investigative Site

Kanazawa, Ishikawa-ken, 920 8650, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 232 0024, Japan
Novartis Investigative Site

Yokosuka, Kanagawa, 239-8567, Japan
Novartis Investigative Site

Kishiwada, Osaka, 596-0042, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 103-0027, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 104-0031, Japan
Novartis Investigative Site

Chuo-ku, Tokyo, 103-0027, Japan
Novartis Investigative Site

Amsterdam, North Holland, 1105 AZ, Netherlands
Novartis Investigative Site

Gdynia, 81-157, Poland
Novartis Investigative Site

Katowice, 40-648, Poland
Novartis Investigative Site

Krakow, 30-002, Poland
Novartis Investigative Site

Wroclaw, 52-416, Poland
Novartis Investigative Site

Bardejov, 085 01, Slovakia
Novartis Investigative Site

Košice, 040 01, Slovakia
Novartis Investigative Site

Nitra, 949 11, Slovakia
Novartis Investigative Site

Svidník, 089 01, Slovakia
Novartis Investigative Site

Seville, Andalusia, 41014, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Terrassa, Catalonia, 08221, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Barcelona, 08025, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 110, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taoyuan District, 33305, Taiwan
Novartis Investigative Site

London, GBR, EC1M 6BQ, United Kingdom
Novartis Investigative Site

London, W1T 7HA, United Kingdom
Novartis Investigative Site

Salford, M6 8HD, United Kingdom
Orange County Research Center

Tustin, California, 92780, United States
Parkway Medical Center

Birmingham, Alabama, 35206, United States
Pinnacle Research Group Llc

Anniston, Alabama, 36207, United States
Tennessee Center For Clinical Trials

Tullahoma, Tennessee, 37388, United States
The Research Center of the Upstate

Greenville, South Carolina, 29607, United States

Conditions

Explore the condition pages connected to this study.

RESISTANT HYPERTENSION